Impotence Plus Heart Disease Ups Death Risk: Men with heart disease who also complain of erectile dysfunction die sooner than other male heart patients, researchers report. They found that men who had both conditions were twice as likely to die from any cause and twice as likely to have a …
Read More »Diabetes In Control
Drugs Don’t Reduce Heart Problems for Diabetes Patients
Key results from a landmark federal study are in and the results are disappointing for diabetes patients: adding drugs to drive blood pressure and blood-fats lower than current targets did not prevent heart problems, and in some cases caused harmful side effects.
Read More »Link between Hypoglycemia and Mortality Rates in Critically Ill
Researchers report that they have found a link between mild to moderate hypoglycemia (low blood sugar) and mortality in critically ill patients.
Read More »No Benefit in Adding Fenofibrate to Statin for Preventing Cardiovascular Events
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid trial, the combination of fenofibrate and simvastatin, compared with simvastatin alone, failed to reduce cardiovascular events in the majority of patients with Type 2 diabetes at high risk for cardiovascular disease.
Read More »FDA Approves Combined Diabetes Management System
The FDA approved Medtronic’s MiniMed Paradigm REAL-Time Revel System, a diabetes management system that combines an insulin pump with a glucose monitoring system. The system may represent the next step toward an artificial pancreas.
Read More »Salsalate Shows Promise in Treating Type 2 Diabetes
Treatment with salsalate lowers levels of hemoglobin A1c (HbA1c) and improves markers of glycemic control and coronary risk in people with Type 2 diabetes, according to a new study.
Read More »Tight Blood Pressure Control Not Supported in Patients with Diabetes and Coronary Artery Disease
Current blood pressure (BP) guidelines for individuals with diabetes (systolic BP [SBP]
Read More »Insulin Glargine Safety in Pregnancy
Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy. However, the placental pharmacokinetics of insulin glargine have not been studied.
Read More »Potential New Anti-Inflammatory Drug for Type 2 Diabetes
An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.
Read More »Urinary Albumin Excretion Predicts Future Cardiovascular Disease, Hypertension, and Kidney Disease
Overall, physical activity was inversely and independently associated with albuminuria. This association held for both walking and strenuous activity.…
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.